Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLITone Alternaria is a sublingual immunotherapy (SLIT) product containing standardized extracts of the mold *Alternaria alternata*, designed for the treatment of respiratory allergies such as allergic rhinitis and mild asthma in patients sensitized to *Alternaria* allergens. The therapy works by gradually exposing the immune system to controlled doses of *Alternaria* allergen via sublingual administration, aiming to induce immune tolerance and reduce allergic symptoms over time. The major allergenic component targeted is Alt a 1, which plays a key role in triggering type 2 inflammatory responses associated with allergy symptoms. Clinical studies have shown that SLIT with *Alternaria* extract can significantly improve symptoms and reduce medication use compared to placebo, with a favorable safety profile[2][3][5]. Developed as an etiological (disease-modifying) treatment rather than symptomatic relief, it is particularly indicated for patients whose allergies are not adequately managed by conventional pharmacotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SLITone Alternaria.